Objectives-To determine the utility of contrast-enhanced ultrasound (US) for characterizing renal lesions that were indeterminate on prior imaging.
R enal cell carcinoma (RCC) is the most common solid renal neoplasm. Its detection is increasing, and it is the seventh leading cancer type in men in the United States. 1 Small focal renal lesions (<4 cm) are often incidentally detected on computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US) imaging. 2, 3 Most commonly, these lesions are simple cysts. 4 Cystic renal lesions have traditionally been characterized with contrast enhanced CT or MRI according to the Bosniak classification, but it does not apply as well to US. [5] [6] [7] Conventional US can distinguish cystic from solid lesions but has limitations in classifying complex cysts regarding their likelihood of malignancy because of the inability to detect enhancement.
The presence or absence of enhancement within a lesion is essential in determining the risk of malignancy. 5 When a lesion is incidentally discovered on a singlephase or unenhanced CT or MRI examination, it may be indeterminate. Many renal tumors avidly enhance, whereas other hypovascular tumors such as papillary RCCs only have mild enhancement. When there is a question of lesion enhancement on CT, a comparison between unenhanced and post-contrast phase images is necessary. 5 When both phases are available, an increase of 10 to 20 Hounsfield units (HU) is needed as evidence of enhancement. 8 Papillary RCC may show minimal enhancement on CT (<20 HU increase between unenhanced and postcontrast images), leading to a falsenegative result. 9 Even when unenhanced and postcontrast images are available, pseudoenhancement is a potential cause of a false-positive CT results in small renal lesions. 5, 10 Magnetic resonance imaging relies on the detection of gadolinium-based contrast within a lesion to determine malignant potential. 11 When a lesion contains T1 hyperintense material, subtraction images can facilitate detection of contrast enhancement; however, detection of small enhancing components within a cystic lesion can be challenging and possibly indeterminate. 12 Some patients cannot undergo contrastenhanced CT or MRI because of decreased renal function and risk of renal damage or nephrogenic systemic fibrosis.
Contrast-enhanced US is increasingly being used to evaluate renal lesions. Microbubbles consist of a lowsolubility complex gas surrounded by a shell typically composed of phospholipids. 13 The microbubbles are suspended in saline and administered intravenously. The size of the microbubbles is similar to that of a red blood cell, and the microbubbles are purely intravascular agents. After injection, the microbubbles have a half-life of approximately 5 minutes in the circulation, which allows for multiple injections in a single patient encounter, if needed. The lungs exhale the microbubble contents, and the liver metabolizes the microbubble shell. Microbubbles are not nephrotoxic, and there is a low incidence of side effects. A strength of contrast-enhanced US is its ability to be used in patients with impaired renal function or history of a contrast agent allergy. The purpose of this study was to further determine the utility of contrast-enhanced US evaluation to characterize lesions that were previously indeterminate by CT, MRI, or conventional US.
Materials and Methods

Patients
This retrospective study was approved by our Institutional Review Board with waiver of informed consent and was compliant with the Health Insurance Portability and Accountability Act. From 2006 to 2015, a total of 134 renal lesions in 116 consecutive patients were evaluated with contrast-enhanced US at our tertiary care hospital. A review of the medical records was performed to document the indication for contrast-enhanced US, prior comparative studies, follow-up examinations, patient demographics, and pathologic follow-up. The initial imaging study for evaluation of the renal lesions that led to the request for contrast-enhanced US was either unenhanced CT, contrast-enhanced CT, unenhanced MRI, contrast-enhanced MRI, or unenhanced conventional US.
Contrast-Enhanced US
Conventional grayscale US was initially used to localize the renal lesion and determine the best plane for contrast-enhanced US visualization. The contrastenhanced US examinations were performed with an iU22 (Philips Healthcare, Andover, MA) or EPIQ 7 (Philips Healthcare) scanner equipped with a C5-2 or C9-2 transducer. A low mechanical index was used, typically less than 0.1, with individual image optimization. Definity (Lantheus Medical Imaging, North Billerica, MA) or SonoVue (Bracco Imaging, Milan, Italy) contrast material was used as the contrast agent. Each patient was interviewed with a safety questionnaire to assess for any possible contraindication to receiving microbubble contrast agents (history of allergy, pulmonary arterial hypertension). The contrast material dose was given as intravenous bolus injections (after 45-second mechanical activation) through a peripheral intravenous line in the antecubital fossa, administered by a nurse who was present for the entire examination for monitoring. The bolus injection was immediately followed by a 10-mL saline flush. The maximum dose of SonoVue was 2.4 mL. The maximum dose of Definity was 10 lL/kg and given in 0.3-to 0.4-mL increments as needed; occasionally a higher dose was necessary to achieve renal parenchymal enhancement in a patient with end-stage renal disease or chronic kidney disease. Most patients received 1 to 3 doses of contrast material depending on whether there were multiple lesions or additional imaging was necessary. No adverse reactions occurred. A split-image screen was used to monitor contrast enhancement. Imaging was performed for up to 3 minutes after contrast material injection using periods of breath holding when appropriate. Imaging clips were stored in the departmental picture archiving and communication system for additional offline review.
Each contrast-enhanced US study was performed and interpreted in real time by an abdominal imaging fellowship-trained radiologist with 4 to 20 years of experience in contrast-enhanced US and then retrospectively reviewed by a fellowship-trained radiologist with 4 years of experience in contrast-enhanced US on an US picture archiving and communication system (Imorgan, San Mateo, CA). Contrast-enhanced US categorization (illustrated in Figures 1-6 ), for the purposes of statistical analysis is shown in Table 1 : broadly characterized as benign (class A) or potentially malignant (classes B and C). If the lesion was a solid echogenic mass, CT or MRI was required to assess for the presence of fat. As a comparison, cystic lesions were also given a classification based on the Bosniak system. 6 Characterization of the Lesion Before the Contrast-Enhanced US Examination For the retrospective review, an abdominal imaging fellowship-trained radiologist with 4 years of experience reviewed the imaging study performed immediately before each contrast-enhanced US examination. Cystic lesions were classified on CT or MRI according to the Bosniak classification system when possible. 6 If the preceding MRI was an unenhanced study without signal characteristics of a simple cyst (T2 bright/T2 dark with a thin wall), the lesion was considered indeterminate. If the preceding CT was an unenhanced study or venous phase only and the lesion measured greater than 10 HU, the Bosniak score for cystic lesions was assigned as indeterminate, since the presence of contrast enhancement could not be assessed. Lesions were also considered indeterminate on prior CT if there was 10 to 20 HU of enhancement between the unenhanced and postcontrast examinations. 5 The reader was blinded to the results of the contrast-enhanced US study.
Reference Standard A total of 41 patients met the reference standard requirements (histologic diagnosis or follow-up > 1 year). A pathologic diagnosis was obtained for 16 renal lesions by surgical resection or biopsy. Follow-up studies were reviewed to assess for lesion stability or growth over time. Only lesions with greater than 1 year of follow-up were included for analysis (n 5 25). The largest diameter of the lesion was measured at the follow-up examination and compared with the largest diameter when it was first identified. Any lesion that resolved, decreased in size, or was stable at a follow-up study of greater than 1 year was considered benign. Any lesion that grew greater than 20% in maximum diameter on the followup study was considered malignant. 14 The mean followup time was 3.63 years (mean 6 SD, 1326.4 6 1074.8 days; range, 432-4021 days).
Statistical Analysis
The number of lesions definitively characterized by contrast-enhanced US was compared with the indeterminate lesions by prior imaging. The diagnostic accuracy of contrast-enhanced US was calculated by using the pathologic diagnosis as the reference standard, as well as lesion stability. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Corresponding exact 95% confidence intervals (CI) were estimated by the Clopper-Pearson method. Each diagnostic measure was tested against the null value of 0.5 by using an exact binomial distribution. Statistical analysis was performed with SAS version 9.4 software (SAS Institute Inc, Cary, NC) with a 2-sided .05 level of significance. 
Results
Patient demographics are shown in Table 2 . Of the 134 renal lesions evaluated by contrast-enhanced US, 106 were indeterminate by prior imaging. Only the largest lesion per patient was included in the analysis, for a total of 94 lesions. The examinations used for evaluation of the renal lesions before contrast-enhanced US, as well as the reasons why they were indeterminate, are shown in Table 3 . Lesions were indeterminate on conventional US imaging because of the inability to assess for contrast in lesions that did not appear simple. The 94 previously indeterminate lesions are shown in Table 4 .
The median time between the contrast-enhanced US examination and the imaging study immediately preceding it was 43.6 days (mean, 75.0 6 96.2 days). Classification by contrast-enhanced US was made in 95.7% (90 of 94) of the previously indeterminate lesions (95% CI, 91%-99%; P < .0001). Fifty-five were class A (considered benign), 18 class B (potentially malignant cystic masses), 17 class C (potentially malignant solid masses), and 4 remained indeterminate. The lesions that remained indeterminate by contrast-enhanced US were in the setting of acute hemorrhage (n 5 1) or technical limitations due to a large body habitus (n 5 3) with a small lesion diameter (1.1, 1.6, and 2.0 cm). Sixteen of the potentially malignant class B and C lesions went on to pathologic diagnosis (papillary RCC, n 5 9; clear cell RCC, n 5 5; mixed epithelial and stromal tumor, n 5 1; and hemorrhagic cyst, n 5 1). On the basis of the combined follow-up and pathologic reference standard, the sensitivity was 100% (20 of 20; 95% CI, 83%-100%; P < .0001); specificity was 85.7% (18 of 21; 95% CI, 62%-97%; P 5 .0026); positive predictive value was 87.0% (20 of 23; 95% CI, 66%-97%; P 5 .0005), negative predictive value was 100% (18 of 18; 95% CI, 81%- Figure 5 . A solid-appearing left renal lesion was incidentally detected on an abdominal US examination performed for elevated liver function test results. Follow-up contrast-enhanced US showed enhancement of the solid lesion (arrowheads) at the medical aspect of the left kidney (star) and was classified as potentially malignant, class C. This lesion was a clear cell RCC on histopathologic examination. Figure 6 . A left renal mass was incidentally discovered on a CT examination. The lesion measured 39 HU on an unenhanced examination and 55 HU in the nephrographic phase. Given the equivocal enhancement, the mass was indeterminate for an enhancing solid renal mass versus a complex cyst. Homogeneous enhancement was seen within the mass (arrowheads) on contrastenhanced US imaging, with enhancement of less than the adjacent renal parenchyma (stars). This lesion was classified as potentially malignant, class C. The patient underwent partial nephrectomy, and the lesion was a papillary RCC on histopathologic examination. 100%; P < .001); and accuracy was 90.2% (37 of 41; 95% CI, 80%-98%; P < .0001).
Contrast-enhanced US classification based on the reason for a previously indeterminate CT study was assessed. Contrast-enhanced US was definitive for 94.4% (17 of 18) of cases referred because of equivocal enhancement, 100% (36 of 36) of the lesions because of a previous noncontrast technique, and 100% (10 of 10) of the lesions that were previously indeterminate by the presence of only venous-phase images. For the 18 lesions that were previously indeterminate because of equivocal enhancement on CT, contrast-enhanced US showed 10 of these lesions to represent benign lesions (6 were stable at follow-up, 1 was smaller at follow-up, and 3 had no follow-up); 7 represented suspected malignant lesions (2 papillary RCCs, 1 clear cell RCC, 1 stable at 13 months, and 3 with no follow-up), and 1 remained indeterminate because of acute hemorrhage.
When considering the lesions that were indeterminate on prior MRI, contrast-enhanced US was able to classify the lesions in 100% (10 of 10) of the cases. Two lesions were classified as benign (no follow-up), and 8 were classified as potentially malignant (2 that showed growth, 3 papillary RCCs, 1 clear cell RCC, and 1 ablated without biopsy).
Of the 9 papillary RCCs, 5 appeared as solid masses and enhanced less than the adjacent renal cortex, and 4 appeared as mixed solid and cystic lesions. The solid components of the papillary RCCs were isoechoic to hyperechoic to the adjacent renal cortex in 5 of the 9 cases. There were 4 possible lesions detected on preceding CT that were found to represent pseudolesions on contrast-enhanced US imaging and considered benign (2 remained unchanged at follow-up, and 2 did not have follow-up examinations).
When patients were subanalyzed by the underlying reason for the inability to obtain a contrast-enhanced CT or MRI finding, contrast-enhanced US was definitive for characterization of renal lesions in 100% (18 of 18) of patients with end-stage renal disease, in 95.0% (76 of 80) of patients with a glomerular filtration rate of less than 60 mL/min, in 100% (2 of 2) of the patients with history of a contrast agent allergy, and in 100% (9 of 9) of the patients with a renal transplant.
Discussion
As the number of incidentally detected renal lesions increases, the need to determine the malignant potential of each lesion becomes increasingly important. Although conventional US can determine a lesion to be a simple cyst, a contrast-enhanced examination is required if there is internal complexity within the lesion. 15 A precontrast and postcontrast CT examination can often characterize renal lesions, but some patients have contraindications to iodinated contrast (ie, allergy or decreased renal function). Moreover, the CT examination exposes the patient to ionizing radiation, and the lesion may remain indeterminate despite the presence of the dual-phase examination. 16 Magnetic resonance imaging is not as readily available, is limited by cost, has contraindications in cases of a pacemaker or decreased renal function, and can fail to show unequivocal enhancement (particularly in the case of a hypoenhancing solid renal mass in which subtraction images are suboptimal). Contrast enhanced US imaging has been shown to be a sensitive technique Data are presented as mean 6 SD where applicable.
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for detecting vascularity within a complex renal cyst and within a solid renal mass. [17] [18] [19] [20] The real-time benefit of contrast-enhanced US enables assessment of enhancement of a renal mass with regard to the adjacent normal renal parenchyma throughout all phases of enhancement. Evaluation of small indeterminate renal lesions with contrast-enhanced US has been shown to be sensitive and specific. 17 Our findings further validate this concept, as 95.7% (90 of 94) of previously indeterminate renal lesions were successfully characterized with contrast-enhanced US. The use of the Bosniak classification with contrastenhanced imaging is the standard for cystic renal lesion classification. 5 Although the use of the Bosniak classification system was initially proposed for use in CT, it is now also widely used in MRI. Application of the Bosniak classification of renal lesions relies on the presence or absence of contrast enhancement to determine malignant potential. Several previous studies have shown the Bosniak classification of renal lesions by contrastenhanced US to be more sensitive for septations and flow than contrast-enhanced CT [21] [22] [23] ; thus, lesions have been upgraded to a higher Bosniak classification with contrast-enhanced US. 24, 25 Contrast-enhanced US is more likely to show flow within intracystic septa and nodules than CT. 22, 24, 25 The increased sensitivity of contrast-enhanced US leads to potentially decreasing specificity, resulting in a situation in which a lesion that would be classified as nonsurgical by CT or MRI becomes a surgical lesion by contrast-enhanced US.
An initial classification system for contrastenhanced US was proposed, with suggestions for followup, but was not validated by histologic examinations or follow-up results. 26 Barr et al 27 classified renal lesions as benign, indeterminate, or malignant based on the contrast enhancement pattern and found high sensitivity and specificity. The lesions in their study that were classified as indeterminate (enhancing fine septation) remained stable after a 36-month follow-up. 27 Accordingly, we considered lesions with a thin, smooth, enhancing septation as benign, as none showed growth after a follow-up time of 3.6 years, thereby decreasing the potential issue of Bosniak classification upgrading.
Contrast-enhanced US is particularly useful in characterization of previously indeterminate renal lesions. 9, 27, 28 Our findings are in agreement with those of Nicolau et al, 9 who prospectively evaluated 83 renal lesions that were previously indeterminate by CT with sensitivity of 96% (48 of 50) and specificity of 93.9% (31 of 33). Our larger study not only included those lesions that were previously indeterminate by CT but also those that were indeterminate by prior MRI and US. We found slightly lower specificity than the previously published work; there was 1 resected hemorrhagic cyst and 3 lesions that we categorized as potentially malignant that were stable after a follow-up period of greater than 1 year. We considered a lesion stable if it had not grown greater than 20% at follow-up. These lesions may have been slow-growing renal neoplasms that had not yet grown or could have been benign, but longer follow-up may be needed in these individual cases despite the mean follow-up of 3.6 years.
When there is an equivocal increase in attenuation between unenhanced and enhanced CT (10-20 HU), the lesion remains indeterminate despite the presence of both phases and could represent a hypoenhancing renal tumor or a small cyst with pseudoenhancement. 5 This factor is particularly important in the case of hypoenhancing papillary RCCs, which often do not show substantial enhancement. Contrast-enhanced US has been shown to have high sensitivity and specificity in classifying lesions with equivocal enhancement on CT. 21 In our study, we had 18 lesions with equivocal enhancement on the preceding CT that were classified by contrastenhanced US with high sensitivity and specificity.
The differential diagnosis for solid echogenic lesions on US imaging includes angiomyolipoma and RCC. Although angiomyolipomas have been observed to be echogenic with hypoenhancement relative to the adjacent cortex, 27,29 our study included 4 papillary RCCs that were echogenic and hypoenhancing. Atri et al 30 evaluated 94 renal lesions that excluded lipid-rich angiomyolipomas and found that all masses that were less vascular than the adjacent cortex in the arterial phase were malignant. Other series have found that angiomyolipomas retain contrast in the corticomedullary phase, whereas RCCs wash out. 31 Since RCCs may be echogenic, we require unenhanced CT or MRI to confirm the presence or absence of fat regardless of the contrastenhanced US enhancement pattern if a renal mass is echogenic, similar to other practices. 27, 30 Our study had several limitations. It was a retrospective study with a relatively low number of malignant renal lesions. Only a subset of lesions had pathologic diagnoses. We sought to address the limitation of small numbers by using statistically conservative approaches for CI estimation. Additionally, despite our mean followup time of 3.6 years, the RCCs may remain stable in size for several years or may be slow growing 32 and would benefit from further follow-up. However, the benefit of using contrast-enhanced US to assess for enhancement in a renal lesion that was unable to be previously characterized is of great clinical importance and a powerful problem-solving tool.
In conclusion, contrast-enhanced US has a high likelihood of definitively classifying a lesion that was indeterminate by prior CT, MRI, or conventional US. Contrastenhanced US is useful in differentiating benign from neoplastic lesions and can thus guide patient treatment.
